Prevalence and characteristics of persistent taste and smell dysfunction after immune checkpoint inhibitor therapy for cancer
Jip M. van Elst, Corine M Buffinga, Henk S. Brand, Lucie B. M. Hijmering-Kappelle, Harriët Jager-Wittenaar, Anna K. L. Reyners, Janine Nuver, Jacco J. de Haan · 2026
Read Prevalence and characteristics of persistent taste and smell dysfunction after immune checkpoint inhibitor therapy for cancer by Jip M. van Elst, Corine M Buffinga, Henk S. Brand, Lucie B. M. Hijmering-Kappelle, Harriët Jager-Wittenaar, Anna K. L. Reyners, Janine Nuver, Jacco J. de Haan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13194279.txt.
Description
Jip van Elst and seven co-authors checked in two thousand twenty-six whether taste and smell problems linger years after immune therapy for cancer. Immune checkpoint drugs can stir side effects in many organs, and taste and smell shape appetite and quality of life. They compared fifty treated patients with fifty-one caregivers, a median of nearly four years after the last dose.
A small share of patients reported mild or moderate taste changes, more than among caregivers. Patients also rated appetite lower and had higher salt levels in saliva. Yet lab taste and smell tests, spit flow, and dry mouth reports did not differ clearly. Most patients, the authors say, recover fully.
Catalog record
| CREATOR | Jip M. van Elst, Corine M Buffinga, Henk S. Brand, Lucie B. M. Hijmering-Kappelle, Harriët Jager-Wittenaar, Anna K. L. Reyners, Janine Nuver, Jacco J. de Haan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |